Japan's MHLW proposes "drug lag" solution
The early development of two drugs in Japan has been recommended to their relevant pharmaceutical manufacturers by the Study Committee on Usage of Unapproved Drugs within the Japanese Ministry of Health, Labor and Welfare.
These are: Bryan Corp's Aclerosol Intrapleural Aerosol (sterile talc powder 4g), a treatment for malignant pleural effusion, which has been approved in the USA and the European Union; US affiliate of Germany's Schering AG, Berlex' Campath (alemtuzumab), a treatment for B-cell chronic lymphocytic leukemia (CLL), which has been approved in the USA and the European Union.
Concerning the latter drug, the clinical development for the indication for T-cell lymphoma was also urged in addition to CLL because of the presence, in Japan, of relatively large numbers of patients with T-cell lymphoma compared to other countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze